Merck U.S. Human Health
Executive Summary
Realigned operations divided into "customer business units" -- with responsibility for physicians, HMOs, hospitals, group purchasing organizations "and other important customer segments" - - and "region business units" -- with responsibility for six geographic markets, Merck says. Unit President Richard Lane heads the management team that includes Exec VP-Customer Business Units Simon Benito, Senior VP-Region Business Units Martin Carroll and Senior VP-Product Planning & Business Strategy Robert Glaser. Louis Sherwood continues as senior VP-medical & scientific affairs. The reorganization was described by Lane as an effort to make Merck "a more customer-focused operation" ("The Pink Sheet" Nov. 1, T&G-12).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth